Takeda Pharm Stock Price, News & Analysis

Takeda Pharmaceutical Company announced a share buyback plan of up to 100 billion yen, aiming to acquire up to 35 million shares, representing 2.23% of outstanding shares. The initiative is designed to enhance capital efficiency and improve shareholder returns, indicating confidence in the company's cash generation capabilities. The buyback is scheduled from November 2, 2021 to April 29, 2022 and will not affect Takeda's existing deleveraging goals. The company's strong pipeline includes approximately 40 new molecular entities.

Takeda Pharmaceutical Company (NYSE:TAK) reported impressive financial results for H1 FY2021, with a 12.8% increase in reported revenue, amounting to 1,794.4 billion yen ($16.1B), and a 6.8% rise in underlying revenue of 1,661.4 billion yen ($14.9B). The company confirmed its full-year guidance aiming for a 30% core operating profit margin. Further growth is expected through its 14 global brands, which contributed 42% of total core revenue, and a share buyback of up to 100 billion yen highlights confidence in business strategy.

Takeda Pharmaceutical Company has announced its acquisition of GammaDelta Therapeutics, a biotech focused on γδ T cell immunotherapy. This strategic move expands Takeda's capabilities in the immuno-oncology space, targeting solid tumors and blood cancers. The acquisition follows a successful collaboration established in 2017 and involves pre-negotiated upfront and milestone payments. With a focus on off-the-shelf therapies, Takeda aims to enhance patient access to innovative cancer treatments. The deal is set to finalize in Q1 of Takeda's fiscal year 2022, pending regulatory review.

BioLife Plasma Services has opened its first plasma donation center in Worcester, Massachusetts, aiming to meet the urgent demand for plasma-derived therapies for rare and chronic conditions. This center is part of a growing network that currently includes over 160 centers across the U.S. BioLife plans to open additional centers, contributing $2-3 million annually to local communities and creating around 70 jobs per location. The center will begin operations on October 16, with an emphasis on providing an industry-leading donor experience.

Takeda announced that the FDA's Antimicrobial Drugs Advisory Committee unanimously recommended maribavir (TAK-620) for treating refractory cytomegalovirus (CMV) infections in transplant recipients. If approved, maribavir will be the first treatment indicated for adults with this condition. The recommendation is based on results from the Phase 2 and Phase 3 TAK-620-303 (SOLSTICE) trials. The FDA is currently conducting a Priority Review of the New Drug Application (NDA) for maribavir, which has also received Breakthrough Therapy and Orphan Drug designations.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has announced the suspension of patient dosing in its Phase 2 studies of TAK-994, an investigational oral orexin agonist, due to a safety signal. This premature cessation aims to reassess the treatment’s benefit/risk profile. Takeda remains committed to patient safety and plans to evaluate all available data for future development decisions regarding TAK-994. The company continues its focus on its orexin franchise, including TAK-861, which is in Phase 1 development.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has announced new partnerships with IntraHealth International, Jhpiego, Pathfinder International, and the World Food Programme, expanding its Global CSR Program. This initiative has contributed JPY 16.5 billion to 20 programs in 72 countries since its launch in 2016. Key commitments include JPY 953 million for nursing education in West Africa and JPY 1.3 billion for the World Food Programme’s logistics project in Ghana. These partnerships aim to enhance healthcare access and improve health systems, benefiting millions globally.

Mirum Pharmaceuticals has entered into an exclusive licensing agreement with Takeda Pharmaceutical Company for the development and commercialization of maralixibat in Japan. This investigational drug targets rare liver diseases such as Alagille syndrome, progressive familial intrahepatic cholestasis, and biliary atresia. Takeda will oversee regulatory approval and conduct clinical studies. Mirum has also submitted a new drug application for maralixibat in the U.S., with a priority review by the FDA expected by September 29, 2021.